Application of nesitose in the preparation of drugs for treating degenerative diseases of the nervous system

By using Nessel in drugs for treating degenerative neurological diseases, improving paralysis, behavioral changes and brain tissue structure damage, reducing α-synuclein expression and increasing the expression of dopamine-related enzymes, the existing technology has been solved The problem of treating Parkinson's disease has achieved the protection of dopamine neurons and improvement of the disease.

CN116270677BActive Publication Date: 2024-11-29GUANGXI UNIV OF CHINESE MEDICINE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310383105.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-04-12
Publication Date
2024-11-29
Estimated Expiration
2043-04-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat degenerative neurological diseases such as Parkinson's disease, especially the loss of function of dopaminergic neurons and difficulty in maintaining striatal dopamine levels after levodopa medication.

Method used

Using Ness sugar as a drug component, by improving paralysis, behavioral changes, structural damage to the substantia nigra and striatal tissue, reducing α-synuclein expression, and improving the expression of dopamine transporters and tyrosine hydroxylase, To treat degenerative neurological diseases.

Benefits of technology

Nessel significantly improved motor disorders and brain tissue damage in Parkinson's disease mice, reduced α-synuclein expression, and increased the expression of dopamine-related enzymes, thus protecting dopamine neurons.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116270677B_ABST
    Figure CN116270677B_ABST
Patent Text Reader

Abstract

The present invention provides the use of nastose in the preparation of a drug for treating degenerative diseases of the nervous system, and belongs to the field of medical technology. After the administration of nastose, the present invention can significantly improve the movement disorder of mice with Parkinson's disease and improve the motor coordination ability; after the administration of nastose, the structural damage of the substantia nigra and striatum of brain tissue can be significantly improved; nastose significantly reduces the expression of α-synuclein. It shows that nastose has a protective effect on MPTP-induced Parkinson's disease mice, can improve the behavioral changes of animal models, and brain substantia nigra and striatum damage, and the mechanism of action may be related to the protective effect on dopamine neurons by reducing the expression of α-synuclein and increasing DAT and TH.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to the application of nastose in the preparation of medicines for treating degenerative diseases of the nervous system. Background Art

[0002] Parkinson's disease (PD) is a common neurodegenerative disease. Its main pathological features include loss of dopamine neurons in the substantia nigra, the presence of Lewy bodies in the remaining neurons, and degeneration of nerve endings in the striatum. Clinical symptoms include motor symptoms and non-motor symptoms. Non-motor symptoms usually occur much earlier than motor symptoms, often starting in the prodromal stage and worsening throughout the course of the disease, which has a very serious impact on the patient's daily quality of life.

[0003] PD pathology shows degeneration and loss of dopamine (DA) neurons in the substantia nigra reticular zone of the midbrain and decreased DA levels in the striatum. Therefore, levodopa (L-dopa) replacement therapy is the most widely used and effective method. However, with the continuous progression of PD and continued use of levodopa, the remaining dopaminergic neurons lose their ability to produce dopamine, and their buffering capacity for exogenous dopamine drugs decreases. At the same time, dopamine levels in the striatum cannot be maintained at a normal physiological state, which forms abnormal fluctuating stimulation on the dopamine receptors distributed on the surface of medium spiny neurons in the striatum, thereby causing various motor complications involving the head, face, limbs, trunk and other parts. Therefore, exploring new therapeutic targets and alternative therapies and finding new non-dopaminergic drugs have become research hotspots for the treatment of PD. Summary of the invention

[0004] The purpose of the present invention is to provide the use of nesitose in the preparation of drugs for treating neurodegenerative diseases, and nesitose has a protective effect on MPTP-induced Parkinson's disease mice.

[0005] The present invention provides the use of nesitose in preparing medicines for treating degenerative diseases of the nervous system.

[0006] Preferably, the neurodegenerative disease includes Parkinson's disease.

[0007] Preferably, the therapeutic effect of nesitose on Parkinson's disease includes at least one of the following:

[0008] (1) Improve paralysis;

[0009] (2) Improve behavioral changes in Parkinson's patients;

[0010] (3) Improve structural damage to the substantia nigra and / or striatum of brain tissue;

[0011] (4) Reduce the expression of α-synuclein in the substantia nigra of brain tissue;

[0012] (5) Increase the expression of dopamine transporter and / or tyrosine hydroxylase.

[0013] Preferably, the working concentration of nastose is not less than 7.5 mg / kg.

[0014] Preferably, when the nastose is effective in liquid form, the solvent includes physiological saline.

[0015] The present invention also provides a medicine for treating degenerative diseases of the nervous system, which contains nesitose as the only active ingredient and also includes pharmaceutically acceptable excipients.

[0016] The present invention also provides a drug for treating degenerative diseases of the nervous system, which contains nastose and other ingredients having therapeutic effects on degenerative diseases of the nervous system as active ingredients, and also includes pharmaceutically acceptable excipients.

[0017] The present invention also provides a medicine for treating Parkinson's disease, wherein the active ingredient of the medicine includes nesitose and pharmaceutically acceptable excipients.

[0018] Beneficial effects: The present invention provides the use of nastose in the preparation of drugs for treating degenerative diseases of the nervous system. In the embodiment, a Parkinson's disease mouse model was induced by MTPT. After MPTP modeling, the mice developed movement disorders and reduced coordination ability. After administration of nastose, the movement disorders of the mice were significantly improved and the motor coordination ability was improved. At the same time, HE staining was used to observe the substantia nigra structure of the mice. The substantia nigra and striatum of the model group were damaged. After administration of nastose, the damage to the substantia nigra and striatum of the brain tissue was significantly improved. After MPTP modeling, α-synuclein was significantly increased, and nastose could significantly reduce the expression of α-synuclein. It shows that nastose has a protective effect on MPTP-induced Parkinson's disease mice, can improve the behavioral changes of the animal model, and the damage to the substantia nigra and striatum of the brain. The mechanism of action may be related to the protective effect on dopamine neurons by reducing the expression of α-synuclein and increasing DAT and TH. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0020] Figure 1 The results of the effect of NST on the tremor paralysis score of MPTP mice are shown in the figure. Compared with the control group (Control group),### P<0.001; compared with MPTP group, * P<0.05, ** P<0.01, *** P<0.001, the same below;

[0021] Figure 2 This is the result of the open field experiment;

[0022] Figure 3 This is the result of the pole climbing experiment;

[0023] Figure 4 This is the result of the suspension experiment;

[0024] Figure 5 It is a useful experimental result diagram;

[0025] Figure 6 This is a statistical diagram of the behavioral changes of PD mice affected by NST;

[0026] Figure 7 This is the result of HE staining;

[0027] Figure 8 Graph showing the effect of NST on α-synuclein expression;

[0028] Fig. 9 Graph showing the effect of NST on DAT mRNA expression;

[0029] Fig.10 The figure shows the effect of NST on TH mRNA expression. DETAILED DESCRIPTION

[0030] The present invention provides the use of nesitose in preparing medicines for treating degenerative diseases of the nervous system.

[0031] The neurodegenerative diseases of the present invention preferably include Parkinson's disease. In the examples, nysose was used to treat the MTPT-induced Parkinson's disease mouse model, and it was found that nysose can produce the following effects:

[0032] (1) Improve paralysis;

[0033] (2) Improve behavioral changes in Parkinson's patients;

[0034] (3) Improve structural damage to the substantia nigra and / or striatum of brain tissue;

[0035] (4) Reduce the expression of α-synuclein in the substantia nigra of brain tissue;

[0036] (5) Increase the expression of dopamine transporter and / or tyrosine hydroxylase.

[0037] The present invention has no special limitation on the source of nysose, and conventional commercially available test materials in the art can be used with a purity of ≥98%. In the embodiment of the present invention, nysose solution is prepared with physiological saline as solvent, and its working concentration is not less than 7.5 mg / kg.

[0038] The present invention also provides a medicine for treating degenerative diseases of the nervous system, which contains nesitose as the only active ingredient and also includes pharmaceutically acceptable excipients.

[0039] The present invention does not specifically limit the dosage form of the drug, and it can be prepared using appropriate auxiliary materials according to conventional dosage forms in the art, and the working concentration of nesitose is ensured to be no less than 7.5 mg / kg.

[0040] The present invention also provides a drug for treating degenerative diseases of the nervous system, which contains nastose and other ingredients having therapeutic effects on degenerative diseases of the nervous system as active ingredients, and also includes pharmaceutically acceptable excipients.

[0041] The active ingredients of the drug of the present invention include, in addition to nesitose, other ingredients that have therapeutic effects on neurodegenerative diseases such as Parkinson's disease. The present invention has no special restrictions on other active ingredients.

[0042] The present invention also provides a medicine for treating Parkinson's disease, wherein the active ingredient of the medicine includes nesitose and pharmaceutically acceptable excipients.

[0043] The drug of the present invention is preferably the same as described above and will not be described in detail herein.

[0044] To further illustrate the present invention, the application of nastose provided by the present invention in the preparation of drugs for treating neurodegenerative diseases is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0045] Example 1

[0046] 1. Materials and Methods

[0047] MPTP (purity ≥ 98%, Sigma), Nystose (NST) (purity ≥ 98%, McLean), Compound L-dopa Tablets (Shanghai Roche Pharmaceuticals Co., Ltd.).

[0048] 1.1 Experimental animals

[0049] 60 male C57BL / 6 mice, 7-8 weeks old, 25-30 g. The mice were fed adaptively for three days, and all mice were subjected to three open field tests, and mice with abnormal spontaneous behavior were eliminated.

[0050] 1.2 Animal modeling

[0051] 50 mice were randomly selected and given MPTP solution, 30 mg / kg, intraperitoneally, once a day for 7 days. On the seventh day, behavioral test was performed, and when the behavioral test score reached 7.5 points, the model was judged to be successful, and grouping and drug administration began.

[0052] 1.3 Animal grouping

[0053] The mice were divided into 6 groups: blank control group (normal saline 30 mg / kg); model group (MTPT 30 mg / kg); model drug administration group (MPTP+NST high-dose group 30 mg / kg, medium-dose group 15 mg / kg, low-dose group 7.5 mg / kg); model positive control group (compound L-dopamine 30 mg / kg). The solvents of MPTP and NST were both normal saline.

[0054] 1.4 Animal Dosing

[0055] After the mice with successful modeling were grouped, they were weighed and their body weights were recorded every day. The mice were gavaged with 0.1 ml / 10 g of body weight for 14 days, once a day. The appearance and disappearance of the tremor behavior of the animals were observed every two days. On the 7th and 14th days of drug administration, behavioral experimental tests were performed and the scores were recorded. Every other day (referring to the modeling time, the modeling agent was given every other day at the same time as the drug administration) 30 mg / kg of the modeling agent was given to maintain PD symptoms.

[0056] 1.5. Behavioral experiments

[0057] Behavioral tests include: tremor paralysis, open field test, climbing pole test, hanging test and swimming test

[0058] (1) Parkinson's disease

[0059] The mice were observed for tail erection, piloerection, salivation, tremor, paralysis, death, etc. within 1 h after administration, and scored according to their performance: 0 point, similar to normal mice, without any symptoms; 1 point, piloerection, arched back, intermittent fine tremor, but free movement; 2 points, frequent swallowing, frequent tremor, hind limbs spread, tail tremor, and gradually limited movement; 3 points, drooling, continuous tremor, stiff limbs, and limited movement; 4 points, death due to general paralysis.

[0060] (2) Open field test (to determine its activity)

[0061] A 50cm×50cm×50cm square box made of acrylic material was used as the field, which was evenly divided into 9 grids. The mice were placed in the middle grid of the open field, and the number of times the mice stepped into the adjacent grids with more than three paws was recorded. The observation lasted for 2 minutes. The scoring criteria were: 0 points, the number of times of crossing>40 times; 1 point, the number of times of crossing was 31-40 times; 2 points, the number of times of crossing was 21-30 times; 3 points, the number of times of crossing was <21 times.

[0062] (3) Pole climbing test (to determine the condition of the forelimbs)

[0063] Prepare a 25cm long cork ball fixed on the top of a 50cm long and 1cm diameter wooden pole. Wrap the wooden pole with gauze to prevent slipping. Put the mouse to be tested on the ball and record the time it takes for the mouse to climb from the ball to the bottom. The scoring criteria are: 0 points, climbing time <4.01s; 1 point, climbing time 4.01-8.0s; 2 points, climbing time 8.01-12.0s; 3 points, climbing time >12.00s.

[0064] (4) Suspension test (to determine the grasping state of mice)

[0065] The mouse to be tested was hung upside down, and the two front paws were placed at the midpoint of a 30 cm long and 25 cm high horizontal line. The mouse was then released and its grasping condition was recorded. The scoring criteria were: 0 points, both hind paws could grasp the line; the hind paws repeatedly grasped the line, with intermittent grasping, which could be recorded as 0.5 points; 1 point, one hind paw could grasp the line; 2 points, both hind paws could not grasp the line.

[0066] (5) Swimming test (to determine the coordination ability of mice)

[0067] The tested mice were placed in a 40cm×25cm×16cm water tank with a water depth of 15cm and a water temperature of (27±2)℃, and the floating time of the mice was recorded within 3 minutes. The scoring criteria were: 0 points, floating 0-30s; 1 point, floating 31-90s; 2 points, floating 91-150s; 3 points, floating 151-180s; 4 points, choking on water during floating.

[0068] 1.6 Sampling and testing related indicators

[0069] (1) One day after the last administration, brain tissue was obtained for HE staining of the substantia nigra and striatum;

[0070] (2) Immunohistochemical detection of α-synuclein expression in brain tissue;

[0071] (3) qRT-PCR was used to detect the mRNA expression of dopamine transporter (DAT) and tyrosine hydroxylase (TH) in mouse brain tissue.

[0072] DAT upstream primer (SEQ ID NO. 1): 5′-CAGCCTATGGAAGGGAGTAAA-3′;

[0073] Downstream primer (SEQ ID NO. 2): 5′-CAGGAAAGTAGCCAGGACAAT-3′;

[0074] TH upstream primer (SEQ ID NO. 3): 5′-CGAGCTGCTGGGACACGTA-3′;

[0075] Downstream primer (SEQ ID NO.4): 5'-CTGGGAGAACTGGGCAAATG-3';

[0076] GAPDH upstream primer (SEQ ID NO. 5): 5′-GAAGATGGTGATGGGATTT-3′;

[0077] Downstream primer (SEQ ID NO. 6): 5'-CAAGCTTCCCGTTCTCAGCC-3'.

[0078] 2. Experimental results

[0079] 2.1 Effect of NST on Parkinson's disease scores in MPTP mice

[0080] After intraperitoneal injection of MPTP, mice showed erect hair, arched back, intermittent tremor, salivation, limb stiffness, and reduced activity. The NST (7.5mg / kg, 15mg / kg, 30mg / kg) administration group was able to significantly improve the paralysis of mice, and the NST 30mg / kg group had the most significant effect ( Figure 1 ).

[0081] 2.2 Open field experiment

[0082] The open field test results are as follows Figure 2 As shown, the score increased significantly after MPTP modeling, while the NST (7.5 mg / kg, 15 mg / kg, 30 mg / kg) administration group was able to significantly reduce the score, and the effect of the NST 30 mg / kg group was the most significant.

[0083] 2.3 Pole climbing experiment

[0084] The results of the pole climbing test are as follows Figure 3 As shown, the score increased significantly after MPTP modeling, while the NST (7.5 mg / kg, 15 mg / kg, 30 mg / kg) administration group was able to significantly reduce the score, and the effect of the NST 30 mg / kg group was the most significant.

[0085] 2.4 Suspension experiment

[0086] The results of the suspension test are as follows: Figure 4 As shown, the score increased significantly after MPTP modeling, while the NTS (7.5 mg / kg, 15 mg / kg, 30 mg / kg) administration group was able to significantly reduce the score, and the effect of the NTS 30 mg / kg group was the most significant.

[0087] 2.5 Swimming test

[0088] The results of the swimming test are as follows Figure 5 As shown, the score increased significantly after MPTP modeling, while the NST (7.5 mg / kg, 15 mg / kg, 30 mg / kg) administration group was able to significantly reduce the score, and the effect of the NST 30 mg / kg group was the most significant.

[0089] 2.6 Comprehensive Statistics

[0090] The five behavioral scores of the test mice were summed up and the results were as follows: Figure 6 As shown in the figure, compared with the blank group, the score of the model group mice increased significantly, while the NST (7.5mg / kg, 15mg / kg, 30mg / kg) administration group was able to significantly reduce the score, and the NST 30mg / kg group had the most significant effect. This shows that NST has an improving effect on the behavioral changes of PD in mice.

[0091] 2.7 Effects of nesitose on the substantia nigra and striatum structure of brain tissue in MPTP mice

[0092] HE staining results Figure 7 As shown, the substantia nigra and striatum structures of the mouse brain were damaged, and the NST (7.5 mg / kg, 15 mg / kg, 30 mg / kg) administration groups were able to significantly improve the damage to the substantia nigra and striatum structures.

[0093] 2.8 Effect of NST on α-synuclein in the substantia nigra of brain tissue of MPTP mice α-synuclein is a soluble protein expressed in the presynaptic and perinuclear regions of the central nervous system, and is closely related to the pathogenesis and dysfunction of Parkinson's disease. Immunohistochemistry results showed that the expression of α-synuclein in the substantia nigra of brain tissue of mice was significantly increased after MPTP modeling, and NST could significantly reduce the expression of α-synuclein ( Figure 8 ). This indicates that NST can improve Parkinson's disease by reducing α-synuclein.

[0094] 2.9 Effects of nesitose on the expression of dopamine transporter (DAT) and tyrosine hydroxylase (TH) in brain tissue of MPTP mice

[0095] The results of qRT-PCR experiments are shown in Fig. 9 ,10 As shown in the figure, compared with the blank group, the levels of DAT and TH mRNA in the MPTP model group were significantly reduced, while NST (7.5 mg / kg, 15 mg / kg, 30 mg / kg) could significantly increase the levels of DAT and TH mRNA in the mouse brain tissue, indicating that NST has a protective effect on dopamine neurons in the substantia nigra of the MPTP-induced Parkinson's disease mouse model.

[0096] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. The use of nesitose in the preparation of a drug for treating Parkinson's disease, characterized in that: The drug contains nesitose as the only active ingredient. It also includes pharmaceutically acceptable excipients; the working concentration of nastose is not less than 7.5 mg / kg.

Citation Information

Patent Citations

  • Nk1 receptor antagonist composition

    CN101600724A

  • Application of radix ophiopogonis extract in preparation of medicine for preventing or treating Parkinson's disease, medicine and health care product

    CN114767783A

  • Novel glucose oxidase compositions

    US20190175703A1

  • A pharmaceutical composition containing oligosaccharide obtained from morinda root and the procedure thereof

    WO2009155757A1